Immunovant Inc annual free cash flow for fiscal TTM was -$414 million, a decrease of 1.7% from -$407 million in fiscal 2026. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($414M) | ($407M) | ($377M) | ($215M) | ($188M) | ($106M) | ($84M) | ($53M) | ($29M) | — | ($128M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($124M) | ($95M) | ($92M) | ($103M) | ($117M) | ($111M) | ($101M) | ($89M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IMVT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All IMVT financial statements → Interactive IMVT charts →
About TickerBase · Data methodology & sources · Privacy · Terms